Evolyra Therapeutics

Evolyra Therapeutics is an early-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics for oncology. Based in Cambridge, Massachusetts, the company leverages a proprietary platform to identify and optimize molecular glues and other targeted protein degraders. By focusing on high-value, previously undruggable targets, Evolyra aims to provide new treatment options for patients with solid tumors and hematological malignancies. The company was founded by experienced industry leaders and is backed by prominent life science investors, including Atlas Venture. Evolyra's pipeline is currently in the pre-clinical stage, reflecting its commitment to advancing cutting-edge science into transformative medicines.